The Addition of Ixazomib (IXA) to Pomalidomide (POM) and Dexamethasone (DEX) Improves Progression-Free Survival (PFS) for Multiple Myeloma (MM) Patients (Pts) Progressing on Lenalidomide (LEN) as Part of 1st Line Therapy: Results of the Randomized Phase II Alliance Study A061202
- Citation:
- Hemasphere vol 6 (suppl) 858-9
- Meeting Instance:
- EHA 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3494
- Pharmas:
- Celegene, Millennium-Takeda
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Peter Voorhees Vera Suman Yvonne Efebera Noopur Raje Sascha Tuchman Cesar Rodriguez Katelyn Santo Misty Bova-Solem Destin Carlisle Saad Usmani Phil McCarthy Paul Richardson
- Networks:
- LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-NY158, NC002, OH008
- Study
- Alliance-A061202
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords: